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Endothelial lipase (LIPG) and zinc ﬁnger protein 202 (ZNF202) are two pivotal genes in high
density lipoprotein (HDL metabolism). We sought to determine their genetic contribution
to variation in HDL-cholesterol levels by comprehensive resequencing of both genes in 235
individuals with high or lowHDL-C levels.The selected subjectswere 141Whites (High HDL
Group: n= 68, x¯ = 76.90mg/dl; Low HDL Group: n= 73, x¯ = 32.55mg/dl) and 94 Hispan-
ics (High HDL Group: n= 46, x¯ = 74.85mg/dl; Low HDL Group: n= 48, x¯ = 29.95mg/dl).
We identiﬁed a total of 185 and 122 sequence variants in LIPG and ZNF202, respectively.
We found only twomissense variants in LIPG (T111I and N396S) and two in ZNF202 (A154V
and K259E). In both genes, there were several variants unique to either the low or high
HDL group. For LIPG, the proportion of unique variants differed between the high and
low HDL groups in bothWhites (p = 0.022) and Hispanics (p = 0.017), but for ZNF202 this
difference was observed only in Hispanics (p = 0.021).We also identiﬁed a common haplo-
type in ZNF202 amongWhites that was signiﬁcantly associated with the high HDL group
(p = 0.013). These ﬁndings provide insights into the genetics of LIPG and ZNF202, and
suggest that sequence variants occurring with high frequency in non-exonic regions may
play a prominent role in modulating HDL-C levels in the general population.
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INTRODUCTION
There is an inverse relationship between the levels of high den-
sity lipoprotein cholesterol (HDL-C) and the risk of coronary
heart disease (CHD; Emerging Risk Factors et al., 2009). HDL
protects against the development of atherosclerotic cardiovascu-
lar disease, and thus, low HDL-C is a major CHD risk factor.
About one-third of early familial CHD is attributed to low HDL-
C, which is deﬁned as below 40mg/dl (1.0344mmol/l) for both in
men and women (ATP III, 2002). The prevalence of low HDL-C
in the U.S. population was 44.6 million (16.7% of the popula-
tion) in 2005 (Rosamond et al., 2008). Low HDL-C is predictive
of major cardiovascular events in statin-treated patients even in
the presence of low density lipoprotein cholesterol (LDL-C) lev-
els below 70mg/dl (Barter et al., 2007). Recent data suggest that,
in addition to absolute plasma levels, the biological functions of
HDL are important in assessing the role of HDL in CHD and
major cardiovascular events (Vaisar et al., 2007; Besler et al., 2011).
Understanding the genetic basis of the low HDL-C phenotype is,
therefore, important for public health initiatives and policies.
Several studies, including twin studies, suggest that approx-
imately half of the variation in plasma HDL-C levels is under
Abbreviations: apoAI, apolipoprotein AI; apoE, apolipoprotein E; apoB,
apolipoproteinB;BMI,bodymass index;EL,endothelial lipase;HDL-C,highdensity
lipoproteins-cholesterol; LDL-C, low density lipoproteins-cholesterol; LOD score
logarithm of odds; LPL, lipoprotein lipase; MAF, minor allele frequency; SD, stan-
dard deviation; SLVDS, San Luis Valley diabetes study; TC, total cholesterol; TG,
triglycerides; WGA, whole genome ampliﬁcation; ZNF202, zinc ﬁnger protein 202.
genetic control (Prenger et al., 1992; Kronenberg et al., 2002; Lusis
et al., 2004;Wang andPaigen,2005;Qasim andRader, 2006;Goode
et al., 2007). Mutations in several genes related to lipid metabolism
are associated with altered HDL-C levels, including apolipopro-
tein (apo)AI (Yamakawa-Kobayashi et al., 1999), apoE (Srinivasan
et al., 1999), apoB (Peacock et al., 1994), lecithin:cholesterol acyl-
transferase (Kuivenhoven et al., 1997), lipoprotein lipase (LPL;
Fisher et al., 1997), ATP-binding cassette transporter 1 (Brooks-
Wilson et al., 1999), and scavenger receptor BI (Acton et al., 1999).
However, in aggregate, these known mutations account for only
a small proportion of the genetic contribution to HDL-C varia-
tion. The recent meta genome-wide association studies (GWAS)
identiﬁed common variants in 38 loci associated with HDL-C
levels, which included the aforementioned genes as well as sev-
eral additional genes with as yet unknown functions (Teslovich
et al., 2010). Despite the fact that this meta analysis had enor-
mous statistical power, with a sample size of 99,900 individuals,
it explained only 12% of the total HDL variation (or ∼25–
30% of the genetic variance). It was suggested that additional
rare or low frequency variants in these loci might explain the
remaining unknown genetic contribution to the variation in
HDL-C levels. Therefore, the next logical step in deciphering
the genetic basis of HDL-C levels is to perform deep sequenc-
ing of these genes to identify all functional common and rare
variants.
In this study, we have resequenced two important candidate
genes, endothelial lipase (gene: LIPG, protein: EL), and zinc ﬁn-
ger protein 202 (gene: ZNF202, protein: ZNF202), in selected
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individuals with extreme (high or low) HDL-C levels in an effort
to fully explore their genetic roles in relation to HDL-C variation.
The human LIPG gene (Entrez Gene ID 9388, RefSeq ID
NM_006033) is located on chromosome 18q21.1 and spans
34,945 bp with coordinates of 45,342,425 – 45,373,062. The gene
consists of 10 exons with an average length of about 192 bp except
for the partially coding exon 10, which is about 2.2 kb. The total
transcript length of LIPGis 3,927, of which 1,755 bp is part of the
open reading frame, and 2,172 bp covers the 3′ untranslated region
(3′ UTR). Human EL is synthesized as a peptide of 500 amino acid
residues, including a signal peptide of 20 residues. The mature
protein is 480 residues with a molecular weight of 55 kDa prior to
glycosylation. EL is expressed by endothelial cells in several tissues,
including vessels, liver, lung, thyroid, kidney, testis, ovary, and pla-
centa (Lindegaard et al., 2004). EL is a new member of the plasma
lipase family, which also includes LPL and hepatic lipase (HL),
that signiﬁcantly modulates plasma HDL-C Levels (reviewed in
Badellino and Rader, 2004; Das, 2005). EL is the only member of
the lipase family that is synthesized by endothelial cells, and its
expression is up-regulated by inﬂammatory cytokines, suggesting
a role in endothelial homeostasis (Hirata et al., 1999; Jaye et al.,
1999). Several genetic association studies have examined the role
of LIPG variants in HDL metabolism or in CHD (deLemos et al.,
2002; Halverstadt et al., 2003; Ma et al., 2003; Paradis et al., 2003;
Yamakawa-Kobayashi et al.,2003;Mank-Seymour et al.,2004;Hut-
ter et al., 2006; Shimizu et al., 2007; Tang et al., 2008; Brown et al.,
2009; Edmondson et al., 2009; Jensen et al., 2009; Smith et al.,
2009), but with conﬂicting results. On the other hand, several
GWAS studies identiﬁed LIPG as having a signiﬁcant association
with HDL-C levels (Kathiresan et al., 2008; Keebler et al., 2009;
Gupta et al., 2010; Ma et al., 2010; Teslovich et al., 2010).
The ZNF202 gene (Entrez Gene ID 7753, RefSeq ID
NM_003455) is located on chromosome 11q23.3 and spans
36,874 bp with coordinates of 27,148,140 – 27,185,014. The
ZNF202 gene encodes a 648aa protein with a molecular weight
of 74.7 kDa. However, ZNF202 expression is complex, and its
transcription produces 16 different mRNAs which are differen-
tially expressed in different tissues (see AceView, Thierry-Mieg
and Thierry-Mieg, 2006)1. ZNF202 is a master transcriptional
repressor that affects, speciﬁcally, the expression of a number of
genes involved in lipid metabolism (Wagner et al., 2000; Porsch-
Özcürümez et al., 2001; Langmann et al., 2003; Schmitz et al.,
2004). A linkage study of more than 100 large Utah pedigrees with
early CHD found evidence of the familial low HDL-C trait linked
to chromosomal region 11q23 where the ZNF202 locus is located.
This region is distinct from the neighboringAPOAI/CIII/AIV gene
cluster (Kort et al., 2000). In contrast to the linkage and functional
studies, a recent genetic association study did not ﬁnd any associ-
ation between the coding regions of ZNF202 variants and HDL-C
levels (Stene et al., 2006a); however, the same group found a sig-
niﬁcant association between variants of this gene and the risk
of atherosclerosis and ischemic heart disease (Stene et al., 2006b,
2008). None of the GWAS studies of blood lipids (Kathiresan
et al., 2008; Keebler et al., 2009; Gupta et al., 2010; Ma et al., 2010;
1http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html
Teslovich et al., 2010) found ZNF202 to be associated with HDL-C
levels suggesting that it most likely has a modest quantitative trait
locus effect.
MATERIALS AND METHODS
STUDY DESIGN
Population
The San Luis Valley Diabetes Study (SLVDS), which was initiated
in the mid-1980s, was a case-control study of Type 2 diabetes in a
bi-ethnic population of non-Hispanic Whites (Whites) and His-
panics in southern Colorado. The design and objectives of the
population study and methods of measuring various biometrics
have been described in detail (Hamman et al., 1989). The SLVDS
is ideal for association studies and for determining the role of
genetic factors in the development of complex disorders, such as
diabetes and cardiovascular disease. The cardiovascular risk factors
of these two populations have previously been assessed (Burch-
ﬁel et al., 1990). The suitability of the SLVDS population arises
from its stability based on historical demographic records, similar
environmental conditions, and different genetic backgroundswith
little genetic admixture between the two sub-populations (Bonilla
et al., 2004). The entire SLVDS population samples (n = 1791)
consisted of 659 diabetic cases and 1132 normoglycemic controls.
The SI reference range for preprandial normal blood glucose level
is 90–110mg/dl (5–6mmol/l). The control sample,whichwasused
in this sequencing study, included 674 Whites and 458 Hispanics.
The age range of study participants was 20–74 years. The quan-
titative traits related to lipoprotein metabolism of these control
subjects have been summarized and compared between the two
populations (Razzaghi et al., 2000). IRB approval for this study
was obtained.
Selected subjects for resequencing
For the comprehensive DNA resequencing of the LIPG and
ZNF202 genes, 235 individuals (141 Whites and 94 Hispanics)
falling in the upper or lower tenth percentile ranks of the HDL-C
distribution were selected from the SLVDS normoglycemic sub-
jects: 121 subjects in the“LowHDLGroup”(x¯ = 31.24mg/dl) and
114 in the “High HDL Group” (x¯ = 75.90mg/dl; Figure 1A). The
population normoglycemic samples (n = 1132) were ﬁrst divided
based on ethnicity and gender prior to ranking based on HDL-C
level.
DNA samples
After the original study, genomicDNAwas extracted fromblood at
the University of Pittsburgh in the 1980s. Due to limited material
for many of the samples, all selected DNA samples for resequenc-
ing were ampliﬁed using Whole Genomic Ampliﬁcation (WGA),
using Illustra GenomiPhi HY DNA Ampliﬁcation Kit (GE Health-
care). Following genomic ampliﬁcation, the quality of DNA was
assessed by PCR and the amount was quantiﬁed using the Quant-
iT PicoGreen DNA Assay Kit (Molecular Probes). All tested PCR
were of adequate quality. DNA (10.0μg) from each of the 235
samples was seeded in its appropriate coordinates on 96-well
plates. The correct sequential seeding was reconﬁrmed by match-
ing the order of the DNA tubes with the coordinates on the plates.
DNA samples were shipped to the Seattle SNP PGA Center at the
University of Washington for resequencing.
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FIGURE 1 | Study design and summary sequencing results.
(A) Distribution and selection of SLVDS subjects based on their HDL-C levels.
(B) Classiﬁcation of the identiﬁed sequence variants in LIPG and ZNF202 loci.
(C) Assignment of sequence variants to Low or High HDL Group.
Resequencing
The entire length of the LIPG and ZNF202 genes, including
2,000 bp 5′ of exon 1, all exons and introns, and 2,000 bp 3′ of
the last exon, was sequentially ampliﬁed using PCR primers tailed
with universal M13 forward and reverse primer sequences. Con-
trary to the previously proposed 6-exon (Monaco et al., 1998) or
10-exon (Wagner et al., 2000) ZNF202 gene structure, a recent
experimental-data-based capping proﬁle for ZNF202 supports a
9-exon gene structure2. In this structure, the ﬁrst three exons and
part of exon 9 make up the non-coding exons of the gene. We
used the latter gene structure model for this resequencing study.
2http://dbtss.hgc.jp/
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5′-M13 tailed-gene-speciﬁc PCR primers were designed to cover
the target region with amplicon sizes ranging from 500 to 750 bp
and with a minimum of 100 bp overlap between adjacent ampli-
cons, where applicable, and resulted in double-stranded coverage
of all targeted regions. Overlapping amplicons were used to vali-
date gene-speciﬁc primer sequences in independent experiments
and to rule out the possibility of allele-speciﬁc PCR ampliﬁca-
tions. All primer sequences were compared to the whole genome
assembly to verify uniqueness against pseudogenes and gene fam-
ilies. Following temperature gradient optimization of small-scale
reactions to determine optimal thermal cycling conditions, pro-
duction level PCR ampliﬁcations were performed in 96-well plates
in a volume of 7μl comprising 0.2μl each of 7μM forward
and reverse primers, 2.8μl DNA (5 ng/μl), and 0.4μl Elongase
Enzyme (Invitrogen) or iProof polymerase (Bio-Rad) per well.
Following evaluation by 1% agarose gel electrophoresis, reactions
were diluted fourfold to sixfold in ddH2O. Dilution of the prod-
ucts eliminated the need for any puriﬁcation of the PCR products
prior to sequencing. Sequencing reactions were performed in MJ
Tetrad PTC 225 thermal cyclers in 384-well format using 5% BDT
v3.1 sequencing chemistry (ABI). Reaction products were pre-
cipitated in ethanol with CleanSeq magnetic beads (Agencourt).
Perkin Elmer Minitrak,Multiprobe, and Evolution P3 robots were
used to automate liquid handling in the setup of PCR, sequenc-
ing reactions, and precipitation reactions. Reaction products were
air dried and resuspended in 30μl with ddH2O. Chromatograms
were generated from sequence reaction on an Applied Biosys-
tems ABI 3730XL capillary sequencer. Data ﬂow was tracked
using a custom-designed laboratory information management
system (LIMS). Both genes were sequenced from all 235 selected
subjects.
SNP discovery and analysis
All chromatograms were base-called using Phred, assembled into
contigs using Phrap, and scanned for SNPs with PolyPhred, ver-
sion 6.02 (Stephens et al., 2006) to identify polymorphic sites.
Data quality was monitored and assessed at multiple production
checkpoints using numerous methods. For example, each chro-
matogram was trimmed to remove low-quality sequence (Phred
score <25), resulting in analyzed reads averaging> 450 bp with
an average Phred quality of 40. Following assembly of all chro-
matograms onto an initial reference sequence, putative polymor-
phic sites were selectively reviewed by sequence analysts using
Consed (Gordon et al., 1998). Individual polymorphic sites in
regions with lower quality data, ambiguous base calls, or those
identiﬁed using laboratory quality control tools were reviewed
to eliminate potential false positive positions. Outlier genotypes
were scrutinized by data analysts and removed from the dataset if
ambiguous. This approach generates sequence-based SNP geno-
types with >99.9% accuracy. Variants were deposited into a cus-
tom postgreSQL database, formatted, and submitted to dbSNP
for assignment of ss and rs identiﬁcation numbers, which are
provided in LIPG-section 14 and ZNF202-section 14 in Supple-
mentary Material S1 and S2. The sequence variants were also given
a descriptive ID number consisting of the gene name, followed by
a six-digit number indicating the location of the variant within
the sequence. For example, LIPG-007438 is the LIPG variant at a
position 7438 bp from the start of sequencing (2000 bp upstream
of the ﬁrst exon).
MEASUREMENTS
Biometric measurements
Subjects that participated in the SLVDS study had their vari-
ous biometric measurements taken in the 1980s (Hamman et al.,
1989). For this study, we used the biometric dataset for the fol-
lowing parameters: age, race, gender, body mass index (BMI),
total cholesterol (TC), triglyceride (TG), LDL-C, and HDL-C.
The lipid determination was described in detail in the original
paper (Hamman et al., 1989). Brieﬂy, fasting total serum choles-
terol was measured by the esterase-oxidase method; HDL-C was
determined enzymatically following dextran sulfate magnesium
precipitation, and serum triglycerides by the enzymatic method.
The LDL-C value was calculated with the Friedewald equation
when the triglyceride level was less than 400mg/dl. The means of
these quantitative traits were compared using ANOVA following
natural log transformation of BMI, TG, and HDL-C to achieve a
more normal distribution.
STATISTICAL ANALYSES
Haplotype block construction and selection of tag SNPs
Haplotype blocks were constructed based on the algorithm by
Gabriel et al. (2002) as implemented in Haploview (Barrett et al.,
2005). In particular, 95% conﬁdence intervals for the standardized
linkage disequilibrium (LD) coefﬁcient (D′) were constructed for
SNPs with a minor allele frequency (MAF) of 0.05 or higher. If
95% of SNPs were in strong LD, as deﬁned by having the con-
ﬁdence interval for |D′| with a lower bound of at least 0.70 and
an upper bound of at least 0.98, then a block was declared. For
logistic regression, tag SNPs were selected to be a minimal set of
markers, including non-synonymous SNPs, such that all captured
alleles were correlated at r2> 0.80. A list of the tag SNPs for each
gene is provided in the LIPG-section 11 and ZNF202-section 11
in Supplementary Material S1 and S2.
Genetic association tests for extreme HDL groups
Association testing was performed by block for each haplo-
type with a frequency ≥0.05 using a chi-squared statistic as
implemented in Haploview to compare the haplotype frequency
between the high and low HDL groups. To adjust for multiple test-
ing over haplotypes in blocks, 100,000 permutations of the data
were used to build an empirical distribution for the maximum
observed chi-squared statistic. Likewise, for each SNP followed up
for association testing, a chi-squared statistic was used to com-
pare allele frequencies between the high and low HDL group with
multiple testing adjustment based on 100,000 permutations of the
data. Permuted data sets were created by randomly shufﬂing the
group assignment for extreme HDL. This maintains the LD struc-
ture over the entire gene. SNP association tests were performed
as a follow-up to determine if a single variant could explain the
haplotype results.
As a follow-up to ﬁndings from the comparison of haplotype
frequencies, logistic regression was performed based on the tag
SNPs. The logistic regression was adjusted for gender, age, BMI,
and smoking status and utilized the most common haplotype
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as a reference. A global test of association (Schaid et al., 2002)
was conducted to determine whether there was an association
between each variant and extreme HDL grouping. The global test
uses a score statistic to compare the full model containing hap-
lotype effects to that of the null model containing no association
between haplotypes and extreme HDL. p-Values were based on
1000 permutations of the data. The logistic regression analyses
were conducted in R software using the haplo.stats package3.
Analysis of unique and rare variants
A variant was classiﬁed as unique if allelic variation was observed
in only one of the HDL groups. The proportion of unique vari-
ants was compared between the high and low HDL groups using a
3http://mayoresearch.mayo.edu/mayo/research/schaid_lab/software.cfm
two-sample test of proportions. Associations between the location
(exons, introns, 5′ or 3′ ﬂanking regions) of the unique variants
and extreme HDL groups were determined by Fishers Exact Test.
These analyses were repeated for rare variants, where a rare variant
was deﬁned as having a MAF< 0.05.
RESULTS
We resequenced the entire LIPG and ZNF202 genes – including
5′ (2 kb), all exons and introns, and 3′ (2 kb) in 235 subjects (141
Whites, 94 Hispanics), divided into the high and low HDL groups.
Table 1 provides a summary of variables in the subjects analyzed.
By selecting these 235 subjects from both ends of the HDL-C
distribution from each gender, we sought to enrich our screen-
ing for genetic variations affecting HDL-C levels (Figure 1A). A
summary of the resequencing data for both genes is provided in
Figure 1B and in the high and low HDL groups in Figure 1C. The
Table 1 | Biometric measurements in selected subjects in high and low HDL groups.
Ethnicity Sex Measurements (Mean±SD)* Low HDL group (n =121) High HDL group (n =114) p-Value
Whites Male Count (#) 33 31 –
Age (year) 51.02±11.6 53.06±12.7 0.504
BMI (Kg/m2) 27.74±3.1 23.21±2.8 <0.001
TC (mg/dl) 206.84±46.2 216.12±36.4 0.374
TG (mg/dl) 300.13±273.8 96.85±46.4 <0.001
LDL-C (mg/dl) 132.05±29.5 129.24±36.3 0.749
HDL-C (mg/dl) 28.52±2.5 67.52±6.4 <0.001
Range (Min-Max) 20–32 57–82
Female Count (#) 35 42 –
Age (year) 48.99±11.2 57.59±8.0 <0.001
BMI (Kg/m2) 26.85±4.9 23.67±3.6 <0.001
TC (mg/dl) 206.69±46.4 236.00±54.7 0.013
TG (mg/dl) 178.81±76.6 113.69±56.2 <0.001
LDL-C (mg/dl) 134.38±42.1 126.95±48.3 0.473
HDL-C (mg/dl) 36.55±3.2 86.31±8.3 <0.001
Range (Min-Max) 26–40 74–106
Hispanics Male Count (#) 22 24 –
Age (year) 49.10±10.6 56.41±11.6 0.031
BMI (Kg/m2) 27.79±3.7 23.46±3.2 <0.001
TC (mg/dl) 198.83±51.2 225.77±45.4 0.067
TG (mg/dl) 226.25±68.4 119.36±43.4 <0.001
LDL-C (mg/dl) 124.79±53.1 133.17±44.6 0.567
HDL-C (mg/dl) 28.79±3.3 68.73±8.9 <0.001
Range (Min-Max) 17–32 59–93
Female Count (#) 24 24 –
Age (year) 48.40±13.9 52.04±12.0 0.336
BMI (Kg/m2) 28.30±6.9 23.59±3.3 <0.006
TC (mg/dl) 205.04±48.1 232.33±47.3 0.053
TG (mg/dl) 216.67±74.7 96.50±39.9 <0.001
LDL-C (mg/dl) 130.63±41.6 131.99±37.5 0.905
HDL-C (mg/dl) 31.08±3.3 81.04±11.0 <0.001
Range (Min-Max) 22–36 70–120
*The measurements, which are organized based on ethnicity and gender, include age, BMI, body mass index;TC, total cholesterol;TG, triglyceride; LDL-C, low density
lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol. The HDL range from minimum to maximum is provided for the HDL groups. Standard deviation of
the mean (SD) is provided for each group of biometric measurements.
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details of the discovered sequence variants are provided for LIPG
and ZNF202 in Supplementary Material S1 and S2. In addition,
all the sequence variants have been deposited to the NCBI SNP
Database4.
SEQUENCE VARIATION IN THE LIPG GENE
Of the 185 sequence variants observed in the LIPG gene, 137 were
rare (<0.05 frequency) and 48 were common (≥0.05 frequency);
147 of them were present in Whites and 115 were present in His-
panics; 77 were found in both Whites and Hispanics, 70 were
unique to Whites, and 38 were unique to Hispanics (section 8 in
Supplementary Material S1). We identiﬁed two missense muta-
tions in LIPG, one in exon 3 (LIPG-007438, T111I, MAF= 0.27)
and one in exon 8 (LIPG-023529,N396S,MAF= 0.01; section 4 in
Supplementary Material S1). There are at least 49 genomic repeat
4www.ncbi.nlm.nih.gov/SNP
sequences5 within the human LIPG locus. Of the 185 sequence
variants observed, 48 were located within these repeats (sections 5
and 16 in Supplementary Material S1).
Based on common variants, four haplotype blocks were iden-
tiﬁed in both Whites (Figure 2A) and Hispanics (Figure 2B).
However, the structures of the haplotype blocks differed between
the two ethnicities. No haplotype was associated with extreme
HDL groups in Whites (p = 0.7125); but, one haplotype in block
1 (#3: TCAGCTGTTCTTC, frequency= 0.293 and 0.128 in the
high and low HDL groups, respectively) was found to be associ-
ated with high HDL in Hispanics (p = 0.0073; Table 2A; section
12 in Supplementary Material S1). However, after adjusting for
the number of haplotypes tested, this haplotype became border-
line non-signiﬁcant (p = 0.0576). The individual SNPs contained
in block 1 were also tested to see if their allele frequencies dif-
fered between the high and low HDL groups. Three SNPs showed
5www.repeatmasker.org
A B
FIGURE 2 | Haplotype block structure in LIPG. Haplotype block structure is
indicated by triangular segments for LIPG inWhites (A) and in Hispanics (B);
shading indicates strength of linkage disequilibrium as measured by D ′,
which is provided in the intersecting squares. D ′ is not displayed for squares
with D ′ =1. Squares with signiﬁcant linkage disequilibrium (LOD≥2) are
shaded from light pink to red with D ′ =1 being bright red.White and blue
regions lack signiﬁcant linkage disequilibrium (LOD<2) and represent D ′ <1
and D ′ =1, respectively. Spacing of SNPs along gene is given at the top of
the plot. A diagram of the LIPG gene structure is provided over the plot
where the ﬁrst and last SNPs are on the left and right sides of the diagram,
respectively. Under the SNP ID numbers are the index numbers, shown in
bold, for the SNPs based on the map ﬁle. (A) LIPG, Whites, (B) LIPG,
Hispanics. High resolution blocks are provided in a separate ﬁle (see
Supplementary Material S3).
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Table 2 | Haplotype association of LIPG with high and low HDL groups in Hispanics.
The position and frequency of the individual tagged SNPs within the haplotype are provided in panel (A) and their association within the haplotype in Block 1 is given
in panel (B).
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signiﬁcant differences, but after adjustment for multiple testing all
became non-signiﬁcant (Table 2B). Of particular interest was the
non-synonymous SNP T111I (LIPG-007438), whose frequency in
the Hispanic high HDL group (MAF= 0.2935) was almost double
that of the low HDL group (MAF= 0.1395; Figure 1C). Overall,
no haplotype retained signiﬁcance after adjustment for multiple
testing in both population samples.
Weobserved an intriguing trend in the frequency of the rare and
common variants between the high and low HDL groups in both
Whites and Hispanics. The low HDL group had more rare variants
but fewer common variants than the high HDL group (Figure 1C;
section 10 in Supplementary Material S1). In Whites, there were
23 and 39 variants seen only in the high and low HDL groups,
respectively. In Hispanics, there were 14 and 28 variants seen only
in the high and low HDL groups, respectively. The proportion
of rare variants differed signiﬁcantly between the high and low
HDL groups in both ethnicities (Whites: p-value= 0.022,Hispan-
ics:p-value= 0.017). Interestingly,one rare variant (LIPG-022179,
located in intron 6) was found in the low HDL group in both
Whites and Hispanics (section 9 in Supplementary Material S1).
Next we examined whether the number of rare variants unique
to the high and low HDL groups differed by location within
the gene (5′, exons, introns, 3′; Table 3). We found a signiﬁ-
cant relationship between location and HDL groups in Hispanics
(p = 0.0179), which was not observed in Whites (p = 0.3765). For
both Whites and Hispanics, the proportion of rare variants that
a person carried did not differ between the high and low HDL
groups in exons, introns, 5′, 3′ regions (results not shown).
SEQUENCE VARIATION IN THE ZNF202 GENE
A total of 122 sequence variants were observed in the ZNF202
gene; 107 were found in Whites and 85 in Hispanics; 70 were
shared by both ethnic groups; 37 were present only in Whites, and
15 only in Hispanics (section 8 in Supplementary Material S2); 65
of the sequence variants were rare, and 57 were common variants
(section 7 in Supplementary Material S2). The longest intron in
the ZNF202 gene is intron 3 (9,132 bp), which is where 28 of 65
rare variants (43%) and 35 of 57 common variants (61%) were
found. Of 122 variants, only two were missense variants, one in
exon 5 (ZNF202-013891, A154V, MAF= 0.36) and the other in
exon 7 (ZNF202-015468, K259E, MAF= 0.02; section 4 in Sup-
plementary Material S2). Unlike the observed trend in LIPG, we
Table 3 | Sequence variants unique to each HDL group based on their
location within the LIPG gene.
Location Whites Hispanics
Low HDL
Group
High HDL
Group
Low HDL
Group
High HDL
Group
Exons 4 2 0 4
Introns 28 20 25 9
5′ and 3′ 7 1 3 1
Total 39 23 28 14
p-Value 0.3765 0.0179
Bold indicates that p-Value is signiﬁcant.
did not ﬁnd a pattern in the frequency of rare or common variants
in the ZNF202 gene between the high and low HDL groups in
either Whites or Hispanics (section 10 in Supplementary Material
S2). Interestingly, the overall ratio of rare to common variants was
signiﬁcantly higher for LIPG (137/48) than for ZNF202 (65/57;
p = 0.000219). There are 19 genomic repeat sequences (see text
footnote 5) within the human ZNF202 locus, and 19 of the 122
total sequence variants were located within these repeats (sections
5 and 16 in Supplementary Material S2).
There was one haplotype block in theZNF202 gene in both eth-
nic groups (Figures 3A,B), and haplotypes in this block revealed
signiﬁcant associations between the two extreme groups of HDL
(section 12 in Supplementary Material S2). In Whites there were
ﬁve haplotypes with frequency greater than 0.05, and two of them
(#1-W and #2-W) were associated with HDL-C differences, but
only one of them (#2-W) retained signiﬁcance after adjustment
for testing of multiple haplotypes (p = 0.0133; Table 4A). The fre-
quency of this haplotype in the low HDL group (0.187) was almost
half the frequency in the high HDL group (0.321). In Hispanics,
four haplotypes had frequencies greater than 0.05, and one of them
(#1-H) with the frequency of 0.317 showed signiﬁcant associa-
tion (p = 0.0246) with high HDL group, but after adjustment for
multiple testing became non-signiﬁcant (p = 0.0608; Table 4B).
Interestingly, this 50 bp haplotype in Hispanics (#1-H) differed in
only seven bases from the haplotype in Whites (#1-W), but each
had associationwith differentHDLgroups (Table 4C; section 12 in
Supplementary Material S2). Similar observation can be extended
to the next set of the haplotypes comparison (#2-H vs. #2-W)
as well.
To follow-up the haplotype results, 13 SNPs selected from the
haplotypes were tested for allele frequency differences between the
high and lowHDLgroups (Table 5).No SNPs remained signiﬁcant
after correction for multiple testing. These SNPs were in strong LD
with one another.
Also of interest was the number of rare variants unique to the
low HDL group or to the high HDL group. While the observed
number of rare variantswas similar between the high and lowHDL
groups in Whites (21 vs. 17; p = 0.474), the number of rare vari-
ants was signiﬁcantly different in Hispanics (4 vs. 13; p = 0.0213;
Figure 1C; section 9 in SupplementaryMaterial S2). One rare vari-
ant located in intron 3 (ZNF202-006898,MAF= 0.01) was present
in the high HDL group of both Whites and Hispanics. One of
the two non-synonymous variants identiﬁed in our samples was
K259E (ZNF202-015468, MAF= 0.02). This rare missense vari-
ant was predicted by the bioinformatic program SIFT (Ng and
Henikoff, 2001) to be intolerant and by PolyPhen (Ramensky et al.,
2002) to possibly be damaging.
The distribution of rare ZNF202 variants over exons, introns,
and the 5′ and 3′ regions was not signiﬁcantly different between
high and low HDL groups. Additionally, there was no signiﬁcant
relationship between the proportions of rare variants carried by
an individual and their HDL group (results not shown).
To better classify the association between ZNF202 tagSNPs and
the HDL groups, a logistic regression was performed (Table 6),
and based on the global test of association, only Whites demon-
strated a signiﬁcant association between low and highHDL groups
(p = 0.00596).
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A B
FIGURE 3 | Haplotype block structure in ZNF202. Haplotype block
structure is indicated by triangular segments for ZNF202 inWhites (A) and
in Hispanics (B); shading indicates strength of linkage disequilibrium as
measured by D ′, which is provided in the intersecting squares. D ′ is not
displayed for squares with D ′ =1. Squares with signiﬁcant linkage
disequilibrium (LOD≥2) are shaded from light pink to red with D ′ =1 being
bright red.White and blue regions lack signiﬁcant linkage disequilibrium
(LOD<2) and represent D ′ <1 and D ′ =1, respectively. Spacing of SNPs
along gene is given at the top of the plot. A diagram of the ZNF202 gene
structure is provided over the plot where the ﬁrst and last SNPs are on the
left and right sides of the diagram, respectively. Under the SNP ID
numbers are the index numbers, shown in bold, for the SNPs based on
the map ﬁle. (A) ZNF202, Whites, (B) ZNF202, Hispanics. High resolution
blocks are provided in a separate ﬁle (Supplementary Material S3).
In light of the signiﬁcance of microRNAs (miR) in gene reg-
ulation, we looked at the 3′UTR regions of LIPG and ZNF202
for potential miR sites, and determined if any of the identiﬁed
variants in our study were contained in those sites (section 13 in
Supplementary Material S1 and S2). We found one rare variant
(ZNF202-018021) in one individual within the putative binding
site of miR-127, about 360 bases from the stop codon. Because of
the sporadic presence of this variant it was not possible to examine
its impact on HDL-C.
DISCUSSION
The genetic basis of HDL-C levels is complex (Weissglas-Volkov
and Pajukanta, 2010), and inconsistency between genetic associ-
ations and functional studies of its candidate genes can add fur-
ther confusion to this complexity. Two genes, LIPG and ZNF202,
exemplify the complexity. Several functional studies have ﬁrmly
established the role of these two genes in HDL metabolism. Yet,
genetic association studies have produced contradictory results
regarding their roles in modulating HDL-C levels. The goal of
this study was, therefore, to resequence the entire length of these
two genes in 235 subjects with extreme HDL-C levels in order to
identify all variants associated with HDL-C. The subjects were
selected from a bi-ethnic population of Whites and Hispanics
and classiﬁed into high HDL (n = 114) or low HDL (n = 121)
groups.
We identiﬁed 185 and 122 sequence variants in LIPG and
ZNF202 genes, respectively; both common and rare variants were
identiﬁed. We constructed detailed haplotype (multi-site) maps
for both genes in Whites and Hispanics and identiﬁed haplotype
association of ZNF202 and marginal association of LIPG with
HDL-C. The associated sequence variants were common variants
occurring in non-coding regions of the gene. Rare and missense
variants were not associated with HDL-C levels. This pattern sug-
gests that the mechanism of association with HDL-C levels is most
likely mediated through modulatory effects on the expression of
these two genes.
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Table 4 | Haplotype association of ZNF202 between high and low HDL groups inWhites (A) and in Hispanics (B).The sequence identity between
the two signiﬁcant haplotypes associated with low and high HDL groups acrossWhites and Hispanics (C).
The sequence identity between each of the two haplotype pairs is shaded.
LIPG
At least 18 different missense mutations in the human LIPG gene
have been reported in scientiﬁc databases to-date. All but one
(T111I) are rare variants. Our sequence analysis of the LIPG gene
identiﬁed only two coding variants: one common, T111I (LIPG-
007438), and the other rare, N396S (LIPG-023529), with minor
allele frequencies of 0.27 and 0.01, respectively.
SeveralGWAS studies have identiﬁedLIPG as having signiﬁcant
association with HDL-C levels (Kathiresan et al., 2008; Keebler
et al., 2009; Gupta et al., 2010; Ma et al., 2010; Teslovich et al.,
2010). However, the results pertaining to the association of T111I
with HDL-C levels have been inconsistent, as some studies found
an association (Ma et al., 2003; Mank-Seymour et al., 2004; Hutter
et al., 2006; Tang et al., 2008; Smith et al., 2009) while others
did not (Halverstadt et al., 2003; Paradis et al., 2003; Shimizu
et al., 2007; Jensen et al., 2009). Although the impact of the T111I
variant on the bridging function of EL has yet to be evaluated,
recent functional studies indicate T111I has normal lipase activity
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Table 5 | Association results for SNPs in ZNF202.
Ethnicity SNP ID# Location Alleles Associated
allele
Allele frequencies in p-Value p-Value
(Adj)*
High HDL Group Low HDL group
Hispanics ZNF202-012167 Intron 3 (Repeat seq) T/A A 0.490 0.337 0.0337 0.3293
ZNF202-015425 Exon 7 A/G G 0.436 0.283 0.0292 0.2936
ZNF202-015675 Intron 7 C/T T 0.457 0.289 0.0182 0.1927
ZNF202-015746 Intron 7 T/G G 0.457 0.289 0.0182 0.1927
Whites ZNF202-001335 5′ A/G A 0.738 0.625 0.0500 0.3364
ZNF202-004077 Intron 3 G/A G 0.728 0.604 0.0314 0.2404
ZNF202-004434 Intron 3 A/T A 0.732 0.592 0.0156 0.1327
ZNF202-005785 Intron 3 (Repeat seq) T/C T 0.717 0.604 0.0491 0.3342
ZNF202-006182 Intron 3 A/G A 0.721 0.604 0.0405 0.2881
ZNF202-012167 Intron 3 (Repeat seq) T/A T 0.721 0.603 0.0373 0.2775
ZNF202-017663 Exon 9 – UTR T/G G 0.449 0.326 0.0374 0.2790
ZNF202-018311 Exon 9 – UTR G/A A 0.400 0.265 0.0185 0.1461
ZNF202-020107 3′ C/T T 0.414 0.294 0.0370 0.2755
Location within the gene and association with HDL grouping of SNPs within the haplotypes (Table 4).
The grey shaded part indicates that the difference between the two groups. Bold indicates signiﬁcant p-Values.
*Adjusted p-Values are based on 100,000 permutations.
(Edmondson et al., 2009; Smith et al., 2009), and thus it may not
have a major impact on HDL-C levels. In our dataset, the occur-
rence of T111I in Hispanics was twice as common in the high
HDL group as in the low HDL group; in Whites there was no
difference, conﬁrming its elusive association pattern (Figure 1C).
However the elusive association of T111I with HDL-C levels can
be explained by its location within a haplotype block. The T111I
variant (SNP #41, LIPG-007438) resides on different haplotype
blocks, depending on ethnicity (Figure 2). We found in Hispan-
ics, it is part of block 1 and hence carrying the inﬂuence of the
other SNPs in the block on HDL; whereas, in Whites, it is located
in a small but an independent region between Blocks 3 and 4.
Therefore, it has no inﬂuence on HDL by itself.
The raremissense variant,N396S,has been shown to be a causal
variant. Edmondson et al. (2009) showed that N396S is a loss-of-
function variant in EL, and it is associated with an increase in
HDL-C levels of about 8mg/dl. Furthermore, this same group
found a signiﬁcant excess of rare LIPG missense mutations with
loss-of-function unique to subjects with elevated HDL-C. Thus,
the N396S variant may impact HDL-C levels at the population
level only in combination with other rare causal variants. A similar
mechanism, where multiple rare alleles contribute to low HDL-C,
was demonstrated by Cohen et al. (2004) and for hypertriglyc-
eridemia by Johansen et al. (2010). However, our data show this
is not the underlying mechanism in our population sample, as
N396S was the only rare and causal missense variant we found.
Our data suggest that structure/function changes to EL as a
result of these two missense mutations are unlikely to have a major
impact on HDL-C levels, at least in our population samples. The
remaining sequence variants (n = 183) identiﬁed in our study do
not affect structure or function of EL, but some may affect the
regulation of LIPG expression. This obvious deducible conclusion
is in line with the hypothesis that most weak-effect causal variants
are non-coding (Cooper and Shendure, 2011), which is supported
by the collective GWAS evidence that shows about 88% of trait-
associated variants are non-coding (Hindorff et al., 2009), and
functional studies have deﬁned a regulatory role for some of these
variants (Musunuru et al., 2010).
In both Whites and Hispanics, the high HDL groups had more
common variants but fewer rare variants than did the low HDL
groups (Figure 1C; sections 9 and 10 in Supplementary Material
S1). When we determined the locations (5′, exons, introns, 3′) of
variants unique to either low or high HDL group, we observed a
signiﬁcant difference between the two groups. In Hispanics, the
low HDL group had a signiﬁcantly higher number of variants
located in intronic regions of the gene than the high HDL group
(Table 3). This suggests the presence of functional motif(s) in the
intronic regions of the gene that modulate LIPG expression,which
strengthens our hypothesis that causal variants in putative regu-
latory motifs in the non-coding regions of the gene may explain
the wide variation in HDL-C levels observed in the general pop-
ulation. Several LIPG functional studies have shown that even a
modest increase in EL expression has profound effects on HDL
metabolism (Jaye et al., 1999; Ishida et al., 2003; Jin et al., 2003;
Ma et al., 2003; Maugeais et al., 2003; Khetarpal et al., 2011). Thus,
these functional studies support the notion that in a population
where causal missense mutations are rare and few, common SNPs
in regulatory regions of a genemay play amajor role inmodulating
HDL-C levels.
Our data also suggest that the genetic architecture (haplo-
type blocks and SNP patterns) of LIPG is different between
Whites and Hispanics. Although both ethnic groups had four
haplotype blocks, the size of each block was substantially dif-
ferent between them (Figure 2). One of the interesting ﬁndings
in the haplotype analyses was the borderline association of one
haplotype (#3: TCAGCTGTTCTTC) with the high HDL group
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Table 6 | Logistic regression of ZNF202 haplotypes between high and low HDL groups inWhites.
p-values correspond to a test of the null hypothesis that no haplotypes are associated with high or low HDL group. The allele frequencies of the signiﬁcant p-values
(shown in bold) are highlighted in grey shade.The names of the haplotypes were shaded as well to highlight the location of each sequence variants in the haplotypes.
in Hispanics (p = 0.0576). This haplotype was present at a rela-
tively high frequency (0.293 and 0.128 in the high and low HDL
groups, respectively; Table 2A). Within this haplotype, there were
three signiﬁcant SNPs prior to adjustment for multiple testing
(Table 2B), which are located in Exon 1-UTR (LIPG-002229,
MAF= 0.29), Intron 1 (LIPG-002651, MAF= 0.28), and Exon 3
(LIPG-007438, T111I, MAF= 0.27). The ﬁrst two SNPs may be
involved in the regulation of LIPG expression and are excellent
candidates for functional studies. Indeed, using luciferase reporter
assay, Khetarpal et al. (2011) recently showed the common vari-
ant LIPG-002229(rs34474737) decreased promoter activity and
conﬁrmed our ﬁnding that this variant was in strong LD with
non-functional T111I, which was enriched in high HDL group.
We suspect that the borderline adjusted p-value is due to our mod-
erate sample size and hence moderate statistical power; therefore,
we report both the adjusted and unadjusted p-values in the tables.
None of the haplotypes in Whites showed signiﬁcant associations
with either HDL group. Another mechanism that is emerging in
the genetics of complex disorders is the possible involvement of
many common variants, with each having a small effect below a
signiﬁcance threshold, but which collectively may explain most of
the observed variance. This phenomenon has been demonstrated,
for example, in the genetic risk of schizophrenia (International
Schizophrenia Consortium et al., 2009). The SNPs discussed in
the above haplotype may well represent another example of this
mechanism.
ZNF202
In contrast to LIPG, there has been only one genetic study that
examined the association of ZNF202 with the plasma lipid proﬁle.
Stene et al. (2006b) screened the promoter and protein-coding
exons of the ZNF202 in 190 individuals with extreme high or
low levels of HDL-C selected from 9259 Danish adults. They
identiﬁed a total of 17 sequence variants, of which four (A154V,
K259E, V274L, R605W) were in the protein-coding exons. Except
A154V, which had high frequency among the Danish cohort
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(MAF= 0.30), the other three were rare variants. None of the
missense variants identiﬁed had a major contribution to HDL-
C levels. The group also acknowledged limitations of their study
resulting from focusing only on promoter and the protein-coding
exons.
In this study we identiﬁed only two coding variants, A154A
(ZNF202-013891, MAF= 0.36) and K259E (ZNF202-015468,
MAF= 0.02). The latter is a rare missense variant, which by itself
cannot explain the extreme HDL-C levels in our population sam-
ple. The other variant, A154V, is common but little is known
regarding its impact on ZNF202 structure or function. Stene et al.
(2006a) found a signiﬁcant association between this SNP and the
risk of ischemic heart disease (IHD) and myocardial infarction
(MI) in women but not in men. In another follow-up study by the
same group (Stene et al., 2008), it was shown that SNP −660A/G
(MAF= 30%) in the ZNF202 promoter predicted severe athero-
sclerosis and increased risk of IHD. Furthermore, homozygosity
of the variant (GG) reduced the expression of ZNF202 by 60%,
indicating the G allele is associated with reduced transcriptional
activity. Interestingly, they found that the A154V SNP was in tight
LD and strongly correlated with the −660A/G SNP. Our study did
not ﬁnd a signiﬁcant association between A154V and HDL-C. In
our sample, the 660A/GSNP(ZNF202-001310)waspresent at only
0.03 MAF and did not show signiﬁcant association with HDL-C.
Nevertheless, the signiﬁcance of the A154V SNP on the structure
and function of ZNF202 should be assessed independently of its
LD with the 660A/G SNP, as by itself, it could be a causal factor for
alteration in ZNF202 function.
Unlike LIPG, the haplotype block structure for ZNF202 was
similar between Hispanics and Whites and consisted of one block
(Figure 3). Also, the ratio of rare to common variants was sig-
niﬁcantly lower for ZNF202 than for LIPG. This implies that
evolutionary forces have limited leverage on this highly conserved
transcriptional factor gene. We identiﬁed two high frequency hap-
lotypes in Whites, and both showed signiﬁcant association with
HDL grouping (Table 4A; section 12 in Supplementary Mate-
rial S2). One haplotype (#1-W) had a frequency of 0.267 and
was associated with low HDL, while the other (#2-W) had a fre-
quency of 0.253 and was associated with high HDL. However,
only the latter remained signiﬁcant after adjustment for mul-
tiple testing. In Hispanics, there was a haplotype (#1-H) with
frequency of 0.317 that was signiﬁcantly associated with high
HDL group prior to adjusting for multiple testing (Table 4B;
section 12 in Supplementary Material S2). It is noteworthy that
of the 50 nucleotides deﬁning the haplotypes, the difference
between the low HDL haplotype in Whites (#1-W) and the high
HDL haplotype in Hispanics (#1-H) is only seven nucleotides
(Table 4C). These seven may be causal variants with functional
signiﬁcance.
SNPs from these haplotypes were tested for HDL group associ-
ation, but none retained signiﬁcance after adjustment for mul-
tiple testing (Table 5). Two of these SNPs (ZNF202-012167
and ZNF202-005785) were within the genomic dispersed repeat
sequences. The role these repeats may play in modulating HDL-
C levels is currently unclear. Another common SNP (2T⇒G),
ZNF202-176663, with MAF of 0.449 and 0.326 in high and low
HDL groups, respectively, is located in the 3′UTR, which is 2 bp
downstream of the translation stop codon. Stene et al. (2006b)
also found this SNP in their Danish population sample, where it
exhibited an allele frequency of 0.39, and was marginally associ-
ated with low HDL-C levels in men but not women. It will be of
interest to assess this SNP in future functional studies to determine
if it impacts the expression of the ZNF202 gene.
In order to assess differences in ﬁndings between our study and
Stene et al. (2006b), we used logistic regression between extreme
HDL groups and haplotypes carrying tagged SNPs. We found sig-
niﬁcant association, again, only in Whites (Table 6). Furthermore,
this association is not with missense variants but is with variants
in non-coding regions of the gene.
In conclusion, comprehensive resequencing may reveal a more
complete picture of genetic architecture underlying complex traits
than exome-resequencing approach. The ﬁnding in this study that
a fewnon-coding SNPs inLIPG andZNF202 associatedwithHDL-
C levels should provide impetus for pursuing future studies aimed
at elucidating the mechanisms by which non-coding SNPs affect
expression of these two genes.
Limitation of this study
The resequencing of LIPG in this study failed to screen 5773 bp
within intronic segments of the gene (section 3 in Supplemen-
tary Material S1). As a result, there may be additional SNPs in the
missed regions that may be relevant to HDL-C, which could not
be analyzed.
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